Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.

Trial Profile

Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Irinotecan (Primary) ; Fluoropyrimidine derivatives
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms AT FIRST

Most Recent Events

  • 25 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network record.
  • 11 Jul 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top